Articles tagged with 'CRT' | BIOTRONIK

BIOTRONIK - Archive (CRT)

2019
27
May
2019
| 00:00 Europe/Amsterdam
BIOTRONIK announced today that the first patient for the BIO|MASTER.Cor Family study was enrolled at Pauls Stradins Clinical University Hospital in Riga, Latvia at the cardiology department led by Prof. Andrejs Erglis. The patient received a Rivacor ...
Read more
06
May
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced initial enrollment into the BIO-LIBRA study, a first-of-its kind, large-scale prospective study to analyze sex-specific outcomes in patients with non-ischemic cardiomyopathy (NICM) treated with cardiac defibrillator device t...
Read more
29
April
2019
| 00:00 Europe/Amsterdam
BIOTRONIK announced today the availability of its Plexa ProMRI S DX lead, with DF4/IS-1 connector in Europe and the US. The lead is an extension of BIOTRONIK’s Plexa family. Together with the new lead and recently launched Acticor/Rivacor ICD and CRT...
Read more
01
April
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced the launch of its Acticor 7 ICD and CRT-D families, which offer a variety of features that specifically address the needs of Japanese patients. The devices are only 10 mm slim and come with an elliptical BIOshape as well as ...
Read more
14
March
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced FDA approval of the Acticor and Rivacor high-voltage cardiac rhythm management (CRM) device families for treatment of patients with cardiac arrhythmias. The six new tachycardia solutions include Rivacor VR-T, Rivacor DR-T, R...
Read more
11
March
2019
| 00:00 Europe/Amsterdam
BIOTRONIK today announced the European market release of the world’s smallest ICD and CRT-D devices that are approved for 3 Tesla (3T) full-body MRI scans.1 Devices in the Acticor and Rivacor families are only 10 mm slim, with a smooth and ellipti...
Read more
2018
17
December
2018
| 00:00 Europe/Amsterdam
BIOTRONIK has announced first enrollment in a multicenter study that aims to demonstrate that a two-lead cardiac resynchronization therapy (CRT) system with atrial sensing is at least as effective as a conventional three-lead system. BIOTRONIK’s CRT-...
Read more
Tags
PR
CRM
CRT
2017
21
August
2017
| 00:00 Europe/Amsterdam
BIOTRONIK today announced FDA approval and commercial availability of Edora HF-T QP, an MR conditional quadripolar (QP) cardiac resynchronization therapy pacemaker (CRT-P) with MRI AutoDetect technology. With a volume of 15 cc, Edora HF-T QP is th...
Read more
03
August
2017
| 00:00 Europe/Amsterdam
BIOTRONIK’s highest performing cardiac resynchronization therapy defibrillator (CRT-D) is now available in Japan. With several key technologies, the Intica 7 HF-T QP has been developed to offer physicians all-inclusive and individualized solutions fo...
Read more
19
July
2017
| 00:00 Europe/Amsterdam
BIOTRONIK today announced FDA approval and availability of the Intica DX and Intica cardiac resynchronization therapy (CRT)-DX implantable cardioverter defibrillator (ICD) systems. The launch of Intica CRT-DX extends the proven benefits of BIOTRONIK’...
Read more
10
July
2017
| 00:00 Europe/Amsterdam
BIOTRONIK has announced the launch of its Evity cardiac resynchronization therapy pacemaker (CRT-P) in the Japanese market. It is the company’s highest performing CRT-P with a battery life of almost 10 years. Quadripolar technology allows for incr...
Read more
19
June
2017
| 00:00 Europe/Amsterdam
Experts in heart failure management gathered today to discuss varying scientific evidence in their field and how to transfer results into clinical practice. The BIOTRONIK symposium “CRT in 2017: Remaining Challenges and New Opportunities in Heart Fai...
Read more
08
May
2017
| 00:00 Europe/Amsterdam
BIOTRONIK today announced FDA approval of the company’s MultiPole Pacing (MPP) technology, providing physicians with additional treatment options for heart failure patients who have been non-responsive to cardiac resynchronization therapy (CRT).1 MPP...
Read more